High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats

Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women

(2013) Myles Wolf et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bone remodelling is reduced by recovery from iron-deficiency anaemia in premenopausal women

(2013) Ione Wright et al.   JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY

How Can Erythropoeitin-Stimulating Agent Use be Reduced in Chronic Dialysis Patients?

(2013) Shayan Shirazian et al.   SEMINARS IN DIALYSIS

Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study

(2013) Merche Prats et al.   BMC Nephrology

Daily Variability in Mineral Metabolites in CKD and Effects of Dietary Calcium and Calcitriol

(2012) T. Isakova et al.   Clinical Journal of the American Society of Nephrology

Biological Variability of Plasma Intact and C-Terminal FGF23 Measurements

(2012) Edward R. Smith et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Targeted Deletion of Klotho in Kidney Distal Tubule Disrupts Mineral Metabolism

(2012) H. Olauson et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Update on fibroblast growth factor 23 in chronic kidney disease

(2012) Myles Wolf   KIDNEY INTERNATIONAL

Phosphate is a vascular toxin

(2012) Rukshana Shroff   PEDIATRIC NEPHROLOGY

Regulation and Function of the FGF23/Klotho Endocrine Pathways

(2012) Aline Martin et al.   PHYSIOLOGICAL REVIEWS

Low Molecular Weight Iron Dextran Increases Fibroblast Growth Factor-23 Concentration, Together With Parathyroid Hormone Decrease in Hemodialyzed Patients

(2012) Tomasz Hryszko et al.   THERAPEUTIC APHERESIS AND DIALYSIS

Notice

(2012)   Kidney International Supplements

Effect of Intravenous Saccharated Ferric Oxide on Serum FGF23 and Mineral Metabolism in Hemodialysis Patients

(2011) Yoko Takeda et al.   AMERICAN JOURNAL OF NEPHROLOGY

Iron sensing and signalling

(2011) Rayko Evstatiev et al.   GUT

Iron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy Humans

(2011) Erik A. Imel et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

FGF23 induces left ventricular hypertrophy

(2011) Christian Faul et al.   JOURNAL OF CLINICAL INVESTIGATION

Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice

(2011) E. G. Farrow et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effects of Dietary Phosphate and Calcium Intake on Fibroblast Growth Factor-23

(2010) M. G. Vervloet et al.   Clinical Journal of the American Society of Nephrology

Circulating Levels of Soluble Klotho and FGF23 in X-Linked Hypophosphatemia: Circadian Variance, Effects of Treatment, and Relationship to Parathyroid Status

(2010) Thomas O. Carpenter et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

FGF23 Fails to Inhibit Uremic Parathyroid Glands

(2010) R. Canalejo et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Hypophosphatemia induced by intravenous administration of saccharated ferric oxide

(2009) Yuichiro Shimizu et al.   BONE

FGF23 Elevation and Hypophosphatemia after Intravenous Iron Polymaltose: A Prospective Study

(2009) Belinda J. Schouten et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia

(2009) B. J Schouten et al.   ANNALS OF CLINICAL BIOCHEMISTRY

Ferric Gluconate Reduces Epoetin Requirements in Hemodialysis Patients with Elevated Ferritin

(2008) T. Kapoian et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation

(2008) Laura T. Pizzi et al.   KIDNEY INTERNATIONAL